← Patent-cliff monitor small molecule CONTEPO FOSFOMYCIN DISODIUM
Loss of exclusivity January 2039 latest FDA-listed patent expiry
Drug detail Brand name CONTEPO Active ingredient FOSFOMYCIN DISODIUM Strength EQ 6GM BASE/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval October 2025 Marketing status RX
Listed patents Patent Expires Type 11541064 January 2039 use U-4331 9345717 October 2034 use U-4332 10086006 October 2034 use U-4332
Regulatory exclusivity Code Expires GAIN October 2033 NP October 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.